Also, due to the relatively low number of patients receiving consolidation, we were not able to assess the impact of BV maintenance therapy

Also, due to the relatively low number of patients receiving consolidation, we were not able to assess the impact of BV maintenance therapy. progression-free survival after AHSCT was Quinagolide hydrochloride 93 and 62%, respectively. Features of advanced disease at recurrence (mixed cellularity, nodular sclerosing, lymphocyte rich, lymphocyte depleted, not defined, positron emission tomography, autologous hematopoietic stem cell transplantation The median number of prior salvage therapies preceding BV?+?B was 3 (range 1C6). Twenty (48.8%) patients received DHAP, while 4 (9.8%) patients received ifosfamide-based first salvage regimen. Seventeen (41.5%) patients received two or more salvage therapies before BV?+?B, including DHAP, ESHAP, IGEV, and Quinagolide hydrochloride PD-1 inhibitor. Patients received a median of 3 (range 1C6) cycles of BV?+?B. The last salvage regimen before AHSCT was BV?+?B. Treatment response and long-term follow-up Of the 41 evaluable patients, 29 (70.7%) achieved CR with BV?+?B therapy before AHSCT. The ORR was 92.6% overall, with 9 (21.9%) patients having partial remission (PR). Twenty-nine (70.8%) patients were PET-negative, and 12 (29.2%) patients were PET-positive before AHSCT. Of the 14 patients with stage IV disease at cHL progression or relapse, the CR and ORR rates were 64.3 and 85.7%, respectively. Twelve (29.2%) patients relapsed after AHSCT, including 8 (19.5%) patients who underwent AHSCT with PET-negative cHL. With Rabbit polyclonal to AREB6 a median follow-up of 17 (range 2C40) months, 37 patients are alive, two patients died, and two have been lost to follow-up. One patient died of disease progression and one of septic shock. None of the deaths were considered treatment-related. The median 2-year OS and PFS were 93 and 62%, respectively (Fig.?2). Compared with patients with stage ICII cHL at relapse, patients with advanced disease features at recurrence had an inferior outcome (cytomegalovirus, gastrointestinal Discussion To date, three prior phase 1C2 studies and a retrospective analysis evaluated the combination of BV and bendamustine in relapsed or refractory cHL patients. BV?+?B regimen showed marked activity in a heavily pretreated population of patients. LaCasce et al. reported on 55 cHL patients who relapsed after first-line chemotherapy and were treated with BV?+?B within a multicenter, phase 2 trial [16]. The overall response and CR rates were 92.5 and 73.6%, respectively. Those 40 patients, who proceeded to AHSCT, had improved OR (95%) and CR (85%) rates, with a 2-year OS of 94.9% and a 2-year PFS of 69.8%. More than half (56.4%) of this patient population experienced grade 3C4 AEs, with lymphopenia, rash, and hypotension occurring most frequently. The incidence of an infusion-related reaction, defined as fever, chills, dyspnea, flushing, nausea, pruritus, hypotension, or Quinagolide hydrochloride the combination of these, was 60%, which is more than single-agent brentuximab vedotin or bendamustine caused alone (12C15%) [22, 23]. Peripheral neuropathy occurred in 54.4% of the evaluable patients. OConnor et al. treated 37 patients with an ORR of 78% in a phase 2 study population [17]. Forty-three percent of these patients achieved a complete response, while the 2-year OS and PFS were 80 and 62%, respectively. The most common grade 3C4 AEs were neutropenia (35%) and lung infection (14%). Broccoli Quinagolide hydrochloride et al. also observed high remission rates (ORR 80%, CR 75%) and promising 3-year OS and PFS (88.1 and 67.3%, respectively) with BV?+?B in 40 cHL patients, who inadequately responded to standard induction [18]. Martineau et al. administered BV?+?B combination to 80 heavily pretreated, relapsed, or refractory cHL patients. They reported a CR in 49 (65%) of 76 patients evaluable for efficacy, with Quinagolide hydrochloride an estimated 2-year OS and PFS of 88.5 and 64%, respectively. Patients eligible to AHSCT had an improved posttransplant CR rate (81%), compared with patients in the group without AHSCT (49%). The most frequent ( ?30%) toxicities were hematological and infectious [24]. Our results are similar to these data in terms of response rates, estimated survival, and.